Endoangel Withdrawal Overspeed Analysis

NCT ID: NCT05069571

Last Updated: 2021-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1210 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-01

Study Completion Date

2022-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Exploring the relationship between the percentage of overspeed of colonoscopy withdrawal and the rate of adenoma detection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endoangel

Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females who are over 18 years old (inclusive);
2. Enteroscopy and related examinations are needed to further clarify the characteristics of digestive tract diseases;
3. Able to read, understand and sign the informed consent form;
4. The researcher believes that the subject can understand the process of the clinical research, is willing and able to complete all the research procedures and follow-up visits, and cooperate with the research procedures.

Exclusion Criteria

1. Participated in other clinical trials, signed an informed consent form and within the follow-up period of other clinical trials;
2. Abuse of drugs or alcohol or mental disorders in the last 5 years;
3. Women during pregnancy or breastfeeding;
4. Subjects with previous history of bowel surgery;
5. The investigator believes that the subject is not suitable for enteroscopy and related examinations;
6. The investigator believes that the subject is not suitable for high-risk diseases or other special circumstances to participate in clinical trials.
7. Patients with gastrointestinal bleeding;
8. Known or highly suspected allergy to any ingredient of bowel cleansing agent;
9. Restricted activities or any mental or physical condition impairs their ability to drink intestinal cleansing preparations;
10. Known or suspected intestinal obstruction or perforation, toxic megacolon, most colectomy, heart failure (grade III or IV), severe cardiovascular disease, severe liver failure or end, renal insufficiency, etc.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Renmin Hospital of Wuhan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Honggang Yu, Doctor

Role: CONTACT

13871281899

Liwen Yao, Doctor

Role: CONTACT

15827416837

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Honggang Yu, Doctor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EA-21-009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.